Clinical trials: glp1 Agonist
Obesity
Efficacy of Tirzepatide for Weight Management in Patients With Suboptimal Weight Loss After Bariatric Surgery: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Many people who have bariatric (weight-loss) surgery do not lose as much weight as expected, or they regain weight over time. This study will test whether a medicine called tirzepatide can help these patients lose more weight and…
- Trial name
- TirBaS (NCT07829198)
- Testing
- Tirzepatide
- Where
- 3 sites in Portugal
- Volunteers
- 70 people
- Sponsor
- Universidade do Porto
Obesity
Effects of GLP-1 Receptor Agonist on Fat Redistribution and Inflammatory Status
GLP-1 receptor agonists promote fat redistribution in obese women with type 2 diabetes, reduce liver fat content, improve the inflammation state
- Trial name
- NCT02118376
- Testing
- Exenatide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai 10th People's Hospital
Diabetes Mellitus Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone
The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to pioglitazone with or without metformin, over a period of 24 weeks of treatment…
- Trial name
- GETGOAL-P (NCT00763815)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Pioglitazone
- Where
- 150 sites in United States, Austria and 11 more
- Volunteers
- 484 people
- Sponsor
- Sanofi
PCOS, Obesity
PDE-4 Inhibitor Roflumilast and GLP-1 Agonist Liraglutide in Polycystic Ovary Syndrome
The purpose of this study was to determine whether monotherapy treatment with phosphodiesterase-4 (PDE-4) inhibitor roflumilast is more effective than treatment with glucagon-like protein 1 (GLP-1) liraglutide or treatment with…
- Trial name
- NCT02187250
- Testing
- metformin, liraglutide, roflumilast
- Where
- Slovenia
- Volunteers
- 45 people
- Sponsor
- University Medical Centre Ljubljana
Obesity, Type 2 Diabetes Mellitus
Influence of Liraglutide, a GLP-1 Receptor Agonist, on Brown Adipose Tissue (BAT) Activity in Humans
The purpose of this study is to access liraglutide influence brown adipose tissue recruitment and its thermogenic effect through hypothalamic activation in obese individuals.
- Trial name
- i-LAB (NCT02718950)
- Testing
- Liraglutide 3.0 mg
- Volunteers
- 20 people
- Sponsor
- University of Campinas, Brazil
Diabetes Mellitus, Type 2, Nicotine Dependence, Cigarettes
Effect of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Stimulation on Smoking Consumption in Type 2 Diabetes Patients
Diabetes has become an increasingly serious global health issue. In 2024, approximately 537 million adults were living with diabetes, and this number is projected to rise to 783 million by 2045, representing a 46% increase.
- Trial name
- NCT06924697
- Testing
- Application of GLP-1RAs drugs, DPP-4i group
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Shanghai East Hospital
Type 1 Diabetes Mellitus, Overweight and Obesity
Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity
This study is a 2-arm, double blinded, randomised clinical trial where 40 participants will be assigned 1:1 to insulin treatment alone (control) or insulin treatment and tirzepatide treatment for 32 weeks.
- Trial name
- TZP-T1D (NCT06180616)
- Testing
- Tirzepatide
- Volunteers
- 40 people
- Sponsor
- Royal North Shore Hospital
Normal Weight, Overweight and Obesity
Effect of GLP1 Receptor Agonist on Brain Insulin Responsiveness
The overarching goal of the current study is to investigate the effect of GLP-1 on brain insulin responsiveness in a randomized, single-blinded, within subject cross-over study design.
- Conditions
- Normal Weight, Overweight and Obesity, Insulin Sensitivity, Insulin Resistance
- Trial name
- NCT06487832
- Testing
- Subcutaneous GLP1-RA
- Where
- Germany
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University Hospital Tuebingen
Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS)
IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion
The goal of this study is to learn how two treatments-adrenalectomy (surgical removal of an adrenal gland) and semaglutide (a medication used for weight management)-affect insulin resistance and cortisol regulation in adults with…
- Conditions
- Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS), Subclinical Cushing's, Mild Autonomous Cortisol Excess
- Trial name
- IMPACT-MACS (NCT07361874)
- Testing
- Intervention 1: Adrenalectomy, Intervention 2: Semaglutide
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Texas Southwestern Medical Center
Short Bowel Syndrome
Liraglutide on Decreasing Parenteral Support in Short Bowel Patients (SLIPS)
Pilot study looking at the effect on Liraglutide in the reduction of parenteral support in patients with short bowel.
- Trial name
- SLIPS (NCT03371862)
- Testing
- Liraglutide Pen Injector [Victoza]
- Where
- United Kingdom
- Sponsor
- Imperial College London
Obesity
POSE2.0 With GLP-1 Agonist for Obesity Management
Determine the effect on weight loss and obesity-related comorbidities in patients receiving the POSE 2.0 procedure with sequential use of Liraglutide at 6 months compared to those receiving Liraglutide and then undergoing the…
- Trial name
- NCT05705388
- Testing
- POSE2.0 Endoscopic Gastric Remodeling, Liraglutide injection
- Where
- United Arab Emirates
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Emirates Health Services (EHS)
Aging, Obesity & Overweight
Assessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical Clock
This study examines whether routine treatment with semaglutide or tirzepatide, prescribed with lifestyle coaching in a real-world weight-management program, is associated with changes in biological age measured by the LinAge2…
- Trial name
- NCT07444073
- Testing
- Not applicable. This is an observational study.
- Where
- 2 sites in Singapore
- Volunteers
- 440 people
- Sponsor
- National University of Singapore
Type 2 Diabetes Mellitus, Congestive Heart Failure
Effects of Exenatide in Type 2 Diabetic Patients With Congestive Heart Failure
The purpose of this study is to determine if exenatide will improve global cardiac function in patients with type 2 diabetes mellitus and congestive heart failure, by favorable effects on cardiac metabolism leading to improvement…
- Trial name
- NCT00766857
- Testing
- exenatide, Insulin glargine
- Where
- Netherlands
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Amsterdam UMC, location VUmc
Muscle Mass
Strength Training Response of Muscle in GLP-1 Users
GLP-1 medication is being prescribed for weight loss. However, GLP-1 medication may adversely affect muscle mass and muscle function.
- Trial name
- STRONG-GLP (NCT07104539)
- Testing
- Strength Training, Wait first, then strength training
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Virginia Polytechnic Institute and State University
Type 2 Diabetes
A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes
The reason for this study is to compare the effect of the study drug tirzepatide to semaglutide on blood sugar levels in participants with type 2 diabetes.
- Trial name
- SURPASS-2 (NCT03987919)
- Testing
- Tirzepatide, Semaglutide
- Where
- 127 sites in United States, Argentina and 7 more
- Volunteers
- 1,879 people
- Sponsor
- Eli Lilly and Company
Healthy
a Study of JY09 in Chinese Healthy Subjects
JY09，is a recombinant glucagon-like peptide-1 (GLP-1) receptor agonist,constructed with Exendin-4 and human Immunoglobulin G2 (IgG2) Fc fragment.Preclinical studies show that JY09 exhibit the expected GLP-1-mediated…
- Trial name
- NCT02971722
- Testing
- JY09
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Beijing Dongfang Biotech Co., Ltd.
Pulmonary Aspiration
Protective Benefits of a Clear Liquid Diet on Residual Gastric Content in Patients Taking Glucagon Like Peptide-1 Receptor (GLP-1 RA) Agonist Prior to Anesthesia
The purpose of this study is to determine if prolonged fasting from solids and transitioning to a CLD for 24 hours is protective to decrease RGC in patients on GLP-1 RAs presenting for upper endoscopy, to determine if prolonged…
- Trial name
- NCT06654219
- Testing
- GLP-1 RA users with prolonged fasting instructions, GLP-1 RA users with standard NPO instructions
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- The University of Texas Health Science Center, Houston
Pre Diabetes, Polycystic Ovary Syndrome
Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS
There is a growing need to develop pharmacologic interventions to improve metabolic function in women with polycystic ovary syndrome (PCOS).
- Conditions
- Pre Diabetes, Polycystic Ovary Syndrome, Obesity Android
- Trial name
- SAXAPCOS (NCT03480022)
- Testing
- Liraglutide Pen Injector [Saxenda]
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Woman's
Obesity, Skeletal Muscle
Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Therapy and Exercise Training in People With Obesity
The use of glucagon-like peptide receptor agonists (GLP-1 RAs) may have clinically important effects on skeletal muscle mass (SMM), and physical function.
- Conditions
- Obesity, Skeletal Muscle, Brain Connectivity
- Trial name
- NCT07091500
- Testing
- Exercise training, Semaglutide, Therapy Cessation
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Washington University School of Medicine
Obesity, Overweight, or Chronic Weight Management
A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity
This study is a randomized, double-blind, placebo-controlled, dose-range finding study of the efficacy, safety, tolerability, PK, and PD of multiple doses of aleniglipron in participants living with overweight or obesity with at…
- Trial name
- ACCESS (NCT06693843)
- Testing
- Aleniglipron
- Where
- 39 sites in United States
- Volunteers
- 230 people
- Sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics